• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血流动力学分类随时间的变化在系统性硬化症相关肺动脉高压中很常见:来自PHAROS队列的见解。

Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort.

作者信息

Lammi Matthew R, Saketkoo Lesley Ann, Gordon Jessica K, Steen Virginia D

机构信息

1 Lousiana State University Health Sciences Center, New Orleans, LA, USA.

2 12255 Comprehensive Pulmonary Hypertension Center-University Medical Center New Orleans, New Orleans, LA, USA.

出版信息

Pulm Circ. 2018 Apr-Jun;8(2):2045893218757404. doi: 10.1177/2045893218757404.

DOI:10.1177/2045893218757404
PMID:29468935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5826006/
Abstract

Group classification of pulmonary hypertension (PH) is based on pulmonary artery wedge pressure (PAWP) on right heart catheterization (RHC). How hemodynamics, particularly PAWP, change over time in systemic sclerosis (SSc)-PH patients is unknown. SSc-PH patients enrolled in the prospective observational PHAROS registry who had > 1 RHC (n = 120) were included in this analysis. Patients were considered to have a "PAWP class change" if they had a PAWP ≤ 15 mmHg on RHC-1 and then a PAWP > 15 on RHC-2 or had a PAWP > 15 on RHC-1 and then PAWP ≤ 15 on RHC-2. There was a median time of 1.4 years between RHC-1 and RHC-2 and 75% of patients had a PH medication added after their initial RHC. PAWP increased significantly (11 ± 5 versus 13 ± 6 mmHg, P = 0.01) between RHC-1 and RHC-2, particularly for patients who were started on PH medications. Overall, 30% of patients who had a repeat RHC experienced a PAWP class change between their initial and follow-up RHC, independent of whether a PH medication was added. Patients initially classified as World Health Organization group 2 PH were most likely to change PAWP class over time. In conclusion, PAWP values commonly change to a significant degree in SSc-PH, which highlights the challenges in using a single time-point PAWP to define clinical classification groups.

摘要

肺动脉高压(PH)的分组是基于右心导管检查(RHC)时的肺动脉楔压(PAWP)。目前尚不清楚在系统性硬化症(SSc)相关性PH患者中,血流动力学,尤其是PAWP,随时间如何变化。本分析纳入了前瞻性观察性PHAROS注册研究中接受过1次以上RHC检查的SSc-PH患者(n = 120)。如果患者在RHC-1时PAWP≤15 mmHg,而在RHC-2时PAWP>15 mmHg,或者在RHC-1时PAWP>15 mmHg,而在RHC-2时PAWP≤15 mmHg,则认为患者发生了“PAWP类别改变”。RHC-1和RHC-2之间的中位时间为1.4年,75%的患者在首次RHC检查后添加了PH药物。RHC-1和RHC-2之间PAWP显著升高(11±5与13±6 mmHg,P = 0.01),尤其是开始使用PH药物的患者。总体而言,30%接受重复RHC检查的患者在初始和随访RHC之间经历了PAWP类别改变,这与是否添加PH药物无关。最初被归类为世界卫生组织第2组PH的患者随着时间推移最有可能改变PAWP类别。总之,在SSc-PH中,PAWP值通常会发生显著变化,这凸显了使用单个时间点的PAWP来定义临床分类组所面临的挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fadb/5826006/b3c2117579c3/10.1177_2045893218757404-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fadb/5826006/5f266273e8be/10.1177_2045893218757404-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fadb/5826006/8cbbf0463b19/10.1177_2045893218757404-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fadb/5826006/2a72d27905ae/10.1177_2045893218757404-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fadb/5826006/b3c2117579c3/10.1177_2045893218757404-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fadb/5826006/5f266273e8be/10.1177_2045893218757404-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fadb/5826006/8cbbf0463b19/10.1177_2045893218757404-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fadb/5826006/2a72d27905ae/10.1177_2045893218757404-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fadb/5826006/b3c2117579c3/10.1177_2045893218757404-fig4.jpg

相似文献

1
Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort.血流动力学分类随时间的变化在系统性硬化症相关肺动脉高压中很常见:来自PHAROS队列的见解。
Pulm Circ. 2018 Apr-Jun;8(2):2045893218757404. doi: 10.1177/2045893218757404.
2
Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.合并肺动脉高压及楔压升高的系统性硬化症患者的临床特征与生存情况:来自PHAROS队列的观察结果
Respirology. 2017 Oct;22(7):1386-1392. doi: 10.1111/resp.13067. Epub 2017 May 12.
3
Fluid loading during the hemodynamic evaluation of pulmonary hypertension: a cross-sectional study.肺动脉高压血流动力学评估期间的液体负荷:一项横断面研究。
Cardiovasc Diagn Ther. 2023 Oct 31;13(5):833-842. doi: 10.21037/cdt-23-59. Epub 2023 Sep 28.
4
Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension.左心房加速因子作为磁共振4D血流测量肺动脉高压患者平均肺动脉楔压的指标
Front Cardiovasc Med. 2022 Aug 3;9:972142. doi: 10.3389/fcvm.2022.972142. eCollection 2022.
5
Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension.系统性硬皮病相关肺动脉高压患者口服血管扩张剂治疗的血液动力学反应。
Cardiovasc Drugs Ther. 2024 Jun;38(3):651-656. doi: 10.1007/s10557-022-07420-1. Epub 2023 Jan 6.
6
Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.硬皮病肺动脉高压评估与转归识别(PHAROS)队列研究中高危系统性硬化症人群肺动脉高压的发生情况
Semin Arthritis Rheum. 2014 Aug;44(1):55-62. doi: 10.1016/j.semarthrit.2014.03.002. Epub 2014 Mar 5.
7
Exercise Hemodynamics for the Diagnosis of Diastolic Dysfunction in Dyspneic Patients with Systemic Sclerosis.运动血流动力学用于诊断系统性硬化症呼吸困难患者的舒张功能障碍
Isr Med Assoc J. 2018 Apr;20(4):245-249.
8
Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia.遗传性出血性毛细血管扩张症中的肺动脉高压。
Chest. 2016 Feb;149(2):362-371. doi: 10.1378/chest.15-0535. Epub 2016 Jan 12.
9
Definitions and diagnosis of pulmonary hypertension.肺动脉高压的定义和诊断。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032.
10
Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system.右心导管检查在左心疾病相关肺动脉高压患者诊断及风险分层中的局限性:来自无线肺动脉压力监测系统的见解
J Heart Lung Transplant. 2015 Mar;34(3):438-47. doi: 10.1016/j.healun.2015.01.983. Epub 2015 Feb 7.

引用本文的文献

1
Comparison of Hemodynamic Effects of Dobutamine and Ephedrine Infusions in Isoflurane-Anesthetized Horses.异氟烷麻醉马中多巴酚丁胺和麻黄碱输注的血流动力学效应比较
Vet Sci. 2023 Apr 6;10(4):278. doi: 10.3390/vetsci10040278.
2
Diversity of hemodynamic types in connective tissue disease associated pulmonary hypertension: more than a subgroup of pulmonary arterial hypertension.结缔组织病相关肺动脉高压的血液动力学类型多样性:不仅仅是肺动脉高压的一个亚组。
BMC Pulm Med. 2022 Aug 1;22(1):295. doi: 10.1186/s12890-022-02081-0.
3
Pulmonary hypertension phenotypes in patients with systemic sclerosis.

本文引用的文献

1
Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement.成人高血压筛查:美国预防服务工作组推荐声明。
Ann Intern Med. 2015 Nov 17;163(10):778-86. doi: 10.7326/M15-2223. Epub 2015 Oct 13.
2
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015年欧洲心脏病学会(ESC)/欧洲呼吸学会(ERS)肺动脉高压诊断和治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断和治疗联合工作组:得到以下组织认可:欧洲儿科和先天性心脏病协会(AEPC)、国际心肺移植学会(ISHLT)。
Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.
3
系统性硬皮病患者的肺动脉高压表型。
Eur Respir Rev. 2021 Aug 17;30(161). doi: 10.1183/16000617.0053-2021. Print 2021 Sep 30.
4
Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.系统性硬化症相关肺动脉高压:系统性筛查诊断和 3 年随访预后。
BMC Pulm Med. 2021 Jul 29;21(1):251. doi: 10.1186/s12890-021-01618-z.
5
Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment.系统性硬化症中的肺动脉高压表型:正确的诊断,正确的治疗。
Int J Mol Sci. 2020 Jun 22;21(12):4430. doi: 10.3390/ijms21124430.
6
Phenotyping pulmonary hypertension in systemic sclerosis: a moving target.系统性硬化症中肺动脉高压的表型分析:一个不断变化的目标。
Pulm Circ. 2018 Apr-Jun;8(2):2045894018785247. doi: 10.1177/2045894018785247.
Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.美国转诊中心使用肺动脉高压获批疗法治疗非1组肺动脉高压的情况。
Pulm Circ. 2015 Jun;5(2):356-63. doi: 10.1086/681264.
4
Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension.运动血流动力学检查可能会在肺动脉高压患者中揭示舒张功能障碍的诊断。
Eur J Heart Fail. 2015 Feb;17(2):151-8. doi: 10.1002/ejhf.198. Epub 2014 Dec 8.
5
Updated clinical classification of pulmonary hypertension.肺动脉高压的最新临床分类。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41. doi: 10.1016/j.jacc.2013.10.029.
6
High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension.在肺动脉高压中,液体冲击试验揭示了隐匿性肺静脉高压的高患病率。
Circ Heart Fail. 2014 Jan;7(1):116-22. doi: 10.1161/CIRCHEARTFAILURE.113.000468. Epub 2013 Dec 2.
7
Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study.肺动脉高压靶向治疗患者右心室功能的心脏磁共振成像测量变化:EURO-MR 研究。
Circ Cardiovasc Imaging. 2014 Jan;7(1):107-14. doi: 10.1161/CIRCIMAGING.113.000629. Epub 2013 Oct 30.
8
Riociguat for the treatment of pulmonary arterial hypertension.利奥西呱特治疗肺动脉高压。
N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655.
9
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.利奥西呱用于治疗慢性血栓栓塞性肺动脉高压。
N Engl J Med. 2013 Jul 25;369(4):319-29. doi: 10.1056/NEJMoa1209657.
10
Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry.诊断为肺动脉高压且肺毛细血管楔压为 16 至 18mmHg 的患者的人口统计学和结局:来自 REVEAL 登记研究的见解。
Chest. 2013 Jan;143(1):185-195. doi: 10.1378/chest.11-1387.